169 related articles for article (PubMed ID: 19809337)
1. A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents.
Swadi HS; Craig BJ; Pirwani NZ; Black VC; Buchan JC; Bobier CM
Int Clin Psychopharmacol; 2010 Jan; 25(1):1-6. PubMed ID: 19809337
[TBL] [Abstract][Full Text] [Related]
2. Switch to quetiapine in antipsychotic agent-related hyperprolactinemia.
Keller R; Mongini F
Neurol Sci; 2002 Dec; 23(5):233-5. PubMed ID: 12522680
[TBL] [Abstract][Full Text] [Related]
3. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
4. Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial.
Byerly MJ; Nakonezny PA; Rush AJ
Psychiatry Res; 2008 May; 159(1-2):115-20. PubMed ID: 18295343
[TBL] [Abstract][Full Text] [Related]
5. Dosing quetiapine in drug-naive first-episode psychosis: a controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumarate in 141 patients aged 15 to 25 years.
Berger GE; Proffitt TM; McConchie M; Kerr M; Markulev C; Yuen HP; O'Donnell C; Lubman D; Polari A; Wood S; Amminger PG; McGorry PD
J Clin Psychiatry; 2008 Nov; 69(11):1702-14. PubMed ID: 19036233
[TBL] [Abstract][Full Text] [Related]
6. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
[TBL] [Abstract][Full Text] [Related]
7. A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning.
Knegtering R; Castelein S; Bous H; Van Der Linde J; Bruggeman R; Kluiter H; van den Bosch RJ
J Clin Psychopharmacol; 2004 Feb; 24(1):56-61. PubMed ID: 14709948
[TBL] [Abstract][Full Text] [Related]
8. [Successful quetiapine therapy in psychotic patients with mood elevation].
Kecskés I
Neuropsychopharmacol Hung; 2009 Dec; 11(4):259-63. PubMed ID: 20150663
[TBL] [Abstract][Full Text] [Related]
9. A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia.
Perez V; Cañas F; Tafalla M;
Int Clin Psychopharmacol; 2008 May; 23(3):138-49. PubMed ID: 18408528
[TBL] [Abstract][Full Text] [Related]
10. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
11. Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach.
Castro-Fornieles J; Parellada M; Soutullo CA; Baeza I; Gonzalez-Pinto A; Graell M; Paya B; Moreno D; de la Serna E; Arango C
J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):327-36. PubMed ID: 18759642
[TBL] [Abstract][Full Text] [Related]
12. Switching female schizophrenic patients to quetiapine from conventional antipsychotic drugs: effects on hyperprolactinemia.
Nakajima M; Terao T; Iwata N; Nakamura J
Pharmacopsychiatry; 2005 Jan; 38(1):17-9. PubMed ID: 15706461
[TBL] [Abstract][Full Text] [Related]
13. Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial.
Katzman MA; Vermani M; Jacobs L; Marcus M; Kong B; Lessard S; Galarraga W; Struzik L; Gendron A
J Anxiety Disord; 2008 Dec; 22(8):1480-6. PubMed ID: 18455360
[TBL] [Abstract][Full Text] [Related]
14. Switching to quetiapine in patients with acute mania who were intolerant to risperidone.
Pae CU; Lee KU; Kim JJ; Lee CU; Bahk WM; Lee SJ; Lee C; Paik IH
Hum Psychopharmacol; 2004 Jan; 19(1):47-51. PubMed ID: 14716712
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study.
Mullen J; Jibson MD; Sweitzer D
Clin Ther; 2001 Nov; 23(11):1839-54. PubMed ID: 11768836
[TBL] [Abstract][Full Text] [Related]
16. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
[TBL] [Abstract][Full Text] [Related]
17. Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled study.
Paleacu D; Barak Y; Mirecky I; Mazeh D
Int J Geriatr Psychiatry; 2008 Apr; 23(4):393-400. PubMed ID: 17879256
[TBL] [Abstract][Full Text] [Related]
18. Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial.
Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Greenspan A
Int J Geriatr Psychiatry; 2005 Dec; 20(12):1153-7. PubMed ID: 16315159
[TBL] [Abstract][Full Text] [Related]
19. An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms.
Timdahl K; Carlsson A; Stening G
Hum Psychopharmacol; 2007 Jul; 22(5):315-25. PubMed ID: 17542047
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials.
Buckley PF
Curr Med Res Opin; 2004 Sep; 20(9):1357-63. PubMed ID: 15383183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
